Generic versus brand-name drugs used in cardiovascular diseases

European Journal of Epidemiology

Volumn 31, Issue 4, 2016, Pages 351-368

  Manzoli, Lamberto ^a,b   Flacco, Maria Elena ^a,b   Boccia, Stefania ^c   D’Andrea, Elvira ^d   Panic, Nikola ^c   Marzuillo, Carolina ^d   Siliquini, Roberta ^e   Ricciardi, Walter ^c,f   Villari, Paolo ^d   Ioannidis, John P A ^g,h  

^a UNIVERSITY OF CHIETI   (Italy)

^b Regional Healthcare Agency of Abruzzo   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h STANFORD UNIVERSITY   (United States)

Author keywords

Brand name drug; Cardiovascular diseases; Efficacy; Generic drug; Meta analysis; Safety

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR AGENT; GENERIC DRUG;

CARDIOVASCULAR DISEASE; EFFECT SIZE; EMBASE; HEALTH CARE ORGANIZATION; HUMAN; MEDLINE; META ANALYSIS; PHYSICIAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCOPUS; SYSTOLIC BLOOD PRESSURE; ADVERSE DRUG REACTION; CARDIOVASCULAR DISEASES; THERAPEUTIC EQUIVALENCE;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; DRUGS, GENERIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THERAPEUTIC EQUIVALENCY;

EID: 84948956815     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-015-0104-8     Document Type: Review

References (112)

1. Dentali F, Donadini MP, Clark N, Crowther MA, Garcia D, Hylek E, et al. Brand name versus generic warfarin: a systematic review of the literature. Pharmacotherapy. 2011;31(4):386–93. doi:10.1592/phco.31.4.386.
2. OECD. OECD. Health at a glance 2013: OECD indicators. Paris: OECD Publishing; 2013. p. 2013.
3. Food and Drug Administration. Generic drugs: questions and answers. US Food and Drug Administration. 2013. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/QuestionsAnswers/ucm100100.htm. Accessed November 2014.
4. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008;300(21):2514–26. doi:10.1001/jama.2008.758.
5. Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs. 2010;70(5):605–21. doi:10.2165/10898530-000000000-00000.
6. Talati R, Scholle JM, Phung OP, Baker EL, Baker WL, Ashaye A, et al. Efficacy and safety of innovator versus generic drugs in patients with epilepsy: a systematic review. Pharmacotherapy. 2012;32(4):314–22. doi:10.1002/j.1875-9114.2012.01099.x.
7. Caldeira D, Fernandes RM, Costa J, David C, Sampaio C, Ferreira JJ. Branded versus generic clopidogrel in cardiovascular diseases: a systematic review. J Cardiovasc Pharmacol. 2013;61(4):277–82. doi:10.1097/FJC.0b013e31827e5c60.
8. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013;369(5):448–57. doi:10.1056/NEJMra1201534.
9. Ashraf T, Ahmed M, Talpur MS, Kundi A, Faruqui AM, Jaffery AH, et al. Competency profile of locally manufactured clopidogrel Lowplat and foreign manufactured clopidogrel Plavix in patients of suspected ischemic heart disease (CLAP-IHD). J Pak Med Assoc. 2005;55(10):443–8.
10. Assawawitoontip S, Wiwanitkit V. A randomized crossover study to evaluate LDL-cholesterol lowering effect of a generic product of simvastatin (Unison Company) compared to simvastatin (Zocor) in hypercholesterolemic subjects. J Med Assoc Thai. 2002;85(Suppl 1):S118–24.
11. Awad R, Arafat T, Saket M, Saleh M, Gharaibeh M, Zmeili S, et al. A bioequivalence study of two products of furosemide tablets. Int J Clin Pharmacol Ther Toxicol. 1992;30(1):18–23.
12. Bongers V, Sabin GV. Comparison of the effect of two metoprolol formulations on total ischaemic burden. Clin Drug Invest. 1999;17:103–10.
13. Carter BL, Gersema LM, Williams GO, Schabold K. Once-daily propranolol for hypertension: a comparison of regular-release, long-acting, and generic formulations. Pharmacotherapy. 1989;9(1):17–22.
14. Carter BL, Noyes MA, Demmler RW. Differences in serum concentrations of and responses to generic verapamil in the elderly. Pharmacotherapy. 1993;13(4):359–68.
15. Chiang HT, Hou ZY, Lee DK, Wu TL, Chen CY. A comparison of antihypertensive effects between two formulations of atenolol: tenolol and tenormin. Zhonghua Yi Xue Za Zhi (Taipei). 1995;55(5):366–70.
16. El-Sayed MS, Davies B. Effect of two formulations of a beta blocker on fibrinolytic response to maximum exercise. Med Sci Sports Exerc. 1989;21(4):369–73.
17. Garg SK, Gupta U, Mathur VS. Comparative bioequivalence study of furosemide in human volunteers. Int J Clin Pharmacol Ther Toxicol. 1984;22(11):618–20.
18. Grahnen A, Hammarlund M, Lundqvist T. Implications of intraindividual variability in bioavailability studies of furosemide. Eur J Clin Pharmacol. 1984;27(5):595–602.
19. Handler J, Nguyen TT, Rush S, Pham NT. A blinded, randomized, crossover study comparing the efficacy and safety of generic Warfarin sodium to Coumadin. Prev Cardiol. 1998;1(4):13–20.
20. Kaojarern S, Poobrasert O, Utiswannakul A, Kositchaiwat U. Bioavailability and pharmacokinetics of furosemide marketed in Thailand. J Med Assoc Thai. 1990;73(4):191–7.
21. Kim SH, Kim YD, Lim DS, Yoon MH, Ahn YK, On YK, et al. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension. Clin Ther. 2007;29(9):1924–36. doi:10.1016/j.clinthera.2007.09.018.
22. Lee HL, Kan CD, Yang YJ. Efficacy and tolerability of the switch from a branded to a generic warfarin sodium product: an observer-blinded, randomized, crossover study. Clin Ther. 2005;27(3):309–19. doi:10.1016/j.clinthera.2005.03.004.
23. Martin BK, Uihlein M, Ings RM, Stevens LA, McEwen J. Comparative bioavailability of two furosemide formulations in humans. J Pharm Sci. 1984;73(4):437–41.
24. Meyer BH, Muller FO, Swart KJ, Luus HG, Werkman IM. Comparative bio-availability of four formulations of furosemide. S Afr Med J. 1985;68(9):645–7.
25. Mignini F, Tomassoni D, Traini E, Amenta F. Single-dose, randomized, crossover bioequivalence study of amlodipine maleate versus amlodipine besylate in healthy volunteers. Clin Exp Hypertens. 2007;29(8):539–52. doi:10.1080/10641960701744046.
26. Mirfazaelian A, Tabatabaeifar M, Rezaee S, Mahmoudian M. Bioequivalence study of atenolol. Daru J Fac Pharm. 2003;11(3):95–8.
27. Murray MD, Haag KM, Black PK, Hall SD, Brater DC. Variable furosemide absorption and poor predictability of response in elderly patients. Pharmacotherapy. 1997;17(1):98–106.
28. Neutel JM, Smith DH. A randomized crossover study to compare the efficacy and tolerability of Barr warfarin sodium to the currently available Coumadin. Cardiovasc Rev Rep. 1998;19(2):49–59.
29. Pan HY, Wang RY, Chan TK. Efficacy of two proprietary preparations of frusemide in patients with congestive heart failure. Med J Aust. 1984;140(4):221–2.
30. Park JY, Kim KA, Lee GS, Park PW, Kim SL, Lee YS, et al. Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine formulations in healthy adult male Korean subjects. Clin Ther. 2004;26(5):715–23.
31. Pereira JA, Holbrook AM, Dolovich L, Goldsmith C, Thabane L, Douketis JD, et al. Are brand-name and generic warfarin interchangeable? Multiple n-of-1 randomized, crossover trials. Ann Pharmacother. 2005;39(7–8):1188–93. doi:10.1345/aph.1G003.
32. Portoles A, Filipe A, Almeida S, Terleira A, Vallee F, Vargas E. Bioequivalence study of two different tablet formulations of carvedilol in healthy volunteers. Arzneimittelforschung. 2005;55(4):212–7. doi:10.1055/s-0031-1296847.
33. Portoles A, Terleira A, Almeida S, Garcia-Arenillas M, Caturla MC, Filipe A, et al. Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): a randomized, two-way, open-label, crossover study in healthy volunteers. Curr Ther Res Clin Exp. 2004;65(1):34–46. doi:10.1016/S0011-393X(04)90003-3.
34. Rao TR, Usha PR, Naidu MU, Gogtay JA, Meena M. Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures. Curr Ther Res Clin Exp. 2003;64(9):685–96. doi:10.1016/j.curtheres.2003.09.014.
35. Sarkar MA, Noonan PK, Adams MJ, O’Donnell JP. Pharmacodynamic and pharmacokinetic comparisons to evaluate bioequivalence of atenolol. Clin Res Regul Aff. 1995;12(1):47–62.
36. Saseen JJ, Porter JA, Barnette DJ, Bauman JL, Zajac EJ Jr, Carter BL. Postabsorption concentration peaks with brand-name and generic verapamil: a double-blind, crossover study in elderly hypertensive patients. J Clin Pharmacol. 1997;37(6):526–34.
37. Sharoky M, Perkal M, Tabatznik B, Cane RC Jr, Costello K, Goodwin P. Comparative efficacy and bioequivalence of a brand-name and a generic triamterene–hydrochlorothiazide combination product. Clin Pharm. 1989;8(7):496–500.
38. Singh A, Gupta U, Sagar S, Garg SK, Sharma BK, Mathur VS. Comparative bioequivalence study of furosemide in patients with edema of renal origin. Int J Clin Pharmacol Ther Toxicol. 1987;25(3):136–8.
39. Tsai YS, Lan SK, Ou JH, Tzai TS. Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan. Clin Ther. 2007;29(4):670–82. doi:10.1016/j.clinthera.2007.04.013.
40. Usha PR, Naidu MUR, Kumar TR, Shobha JC, Vijay T. Bioequivalence study of two slow-release diltiazem formulations using dynamic measures in healthy volunteers. Clin Drug Investig. 1997;14(6):482–6.
41. Waldman SA, Morganroth J. Effects of food on the bioequivalence of different verapamil sustained-release formulations. J Clin Pharmacol. 1995;35(2):163–9.
42. Weibert RT, Yeager BF, Wittkowsky AK, Bussey HI, Wilson DB, Godwin JE, et al. A randomized, crossover comparison of warfarin products in the treatment of chronic atrial fibrillation. Ann Pharmacother. 2000;34(9):981–8.
43. Wiwanitkit V, Wangsaturaka D, Tangphao O. LDL-cholesterol lowering effect of a generic product of simvastatin compared to simvastatin (Zocor) in Thai hypercholesterolemic subjects: a randomized crossover study, the first report from Thailand. BMC Clin Pharmacol. 2002;2:1.
44. Maitai CK, Ogeto JO, Munenge RW, Ochieng S, Juma FD. A comparative study of the efficacy of seven brands of frusemide tablets. East Afr Med J. 1984;61(1):6–10.
45. Merali RM, Walker SE, Paton TW, Sheridan BL, Borst SI. Bioavailability and platelet function effect of acetylsalicylic acid. Can J Clin Pharmacol. 1996;3(1):29–33.
46. Kasmer RJ, Nara AR, Green JA, Chawla AK, Fleming GM. Comparable steady-state bioavailability between two preparations of conventional-release procainamide hydrochloride. Drug Intell Clin Pharm. 1987;21(2):183–6.
47. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. London: The Cochrane Collaboration; 2011.
48. Dunlap WP, Cortina JM, Vaslow JB, Burke MJ. Meta-analysis of experiments with matched groups or repeated measures designs. Psychol Methods. 1996;1:170–7.
49. Rosenthal R, Rubin DB. Comparing effect sizes of independent studies. Psychol Bull. 1982;92:500–4.
50. Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med. 2000;19(22):3127–31. doi:10.1002/1097-0258(20001130)19:22<3127:AID-SIM784>3.0.CO;2-M.
51. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167(6):540–50. doi:10.1001/archinte.167.6.540.
52. Pizzi C, Rutjes AW, Costa GM, Fontana F, Mezzetti A, Manzoli L. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol. 2011;107(7):972–9. doi:10.1016/j.amjcard.2010.11.017.
53. Cuadrado A, Rodriguez Gascon A, Hernandez RM, Castilla AM, de la Maza A, Lopez de Ocariz A, et al. In vitro and in vivo equivalence of two oral atenolol tablet formulations. Arzneimittelforschung. 2002;52(5):371–8. doi:10.1055/s-0031-1299900.
54. Jia JY, Zhang MQ, Liu YM, Liu Y, Liu GY, Li SJ, et al. Pharmacokinetics and bioequivalence evaluation of two losartan potassium 50-mg tablets: a single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. Clin Ther. 2010;32(7):1387–95. doi:10.1016/j.clinthera.2010.06.018.
55. Kim SD, Kang W, Lee HW, Park DJ, Ahn JH, Kim MJ, et al. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. Clin Ther. 2009;31(4):793–803. doi:10.1016/j.clinthera.2009.04.017.
56. Carranza MJ, Alvarado JMN, Aguirre CIA. Therapeutic equivalence of only dose of three presentations of captopril in women with essential hypertension. Medicina Interna de Mexico. 2005;21(4):273–81.
57. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. doi:10.1136/bmj.327.7414.557.
58. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ Can Med Assoc J. 2007;176(8):1091–6. doi:10.1503/cmaj.060410.
59. Friedrich JO, Adhikari NK, Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol. 2007;7:5. doi:10.1186/1471-2288-7-5.
60. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820–6.
61. Carlson JD. NCT01149473 (Losartan potassium/hydrochlorothiazide 100/25 mg tablets in healthy subjects under non-fasting conditions). ClinicalTrialsgov. 2010.
62. Carlson JD. NCT01149486 (Losartan potassium/hydrochlorothiazide 100/25 mg tablets in healthy subjects under fasting conditions). ClinicalTrialsgov. 2010.
63. Iqbal M, Khuroo A, Batolar LS, Tandon M, Monif T, Sharma PL. Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers. Clin Ther. 2010;32(3):588–96. doi:10.1016/j.clinthera.2010.03.004.
64. Kim SH, Chung WY, Zo JH, Kim MA, Chang HJ, Cho YS, et al. Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: an 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial. Clin Ther. 2009;31(5):988–98. doi:10.1016/j.clinthera.2009.05.020.
65. Larouche R. NCT01124162 (Losartan 100 mg tablets in healthy subjects under fasting conditions). ClinicalTrialsgov. 2010.
66. Larouche R. NCT01124175 (Losartan 100 mg tablet in healthy subjects under non-fasting conditions). ClinicalTrialsgov. 2010.
67. Li KY, Liang JP, Hu BQ, Qiu Y, Luo CH, Jiang Y, et al. The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: an open-label, randomized-sequence, single-dose, three-way crossover study. Clin Ther. 2010;32(9):1674–80. doi:10.1016/j.clinthera.2010.08.004.
68. Oigman W, Gomes MA, Pereira-Barretto AC, Povoa R, Kohlmann O, Rocha JC, et al. Efficacy and safety of two ramipril and hydrochlorothiazide fixed-dose combination formulations in adults with stage 1 or stage 2 arterial hypertension evaluated by using ABPM. Clin Ther. 2013;35(5):702–10. doi:10.1016/j.clinthera.2013.03.015.
69. Spinola AC, Almeida S, Filipe A, Neves R, Trabelsi F, Farre A. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions. Clin Ther. 2009;31(9):1992–2001. doi:10.1016/j.clinthera.2009.09.002.
70. Di Girolamo G, Czerniuk P, Bertuola R, Keller GA. Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. Clin Ther. 2010;32(1):161–70. doi:10.1016/j.clinthera.2010.01.010.
71. Khosravi AR, Pourmoghadas M, Ostovan M, Mehr GK, Gharipour M, Zakeri H, et al. The impact of generic form of Clopidogrel on cardiovascular events in patients with coronary artery stent: results of the OPCES study. J Res Med Sci. 2011;16(5):640–50.
72. Komosa A, Siller-Matula JM, Kowal J, Lesiak M, Siniawski A, Maczynski M, et al. Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: plavix and generic-Egitromb. Platelets. 2014;. doi:10.3109/09537104.2013.877581.
73. Mijares M, Gomez M, Quijada A, Borges R, Ruiz-Saez A. Eficacia comparativa de dos presentaciones de clopidogrel en la inhibiciòn de la agregaciòn plaquetaria. Arch Venezo Farmacol Terap. 2008;27(1):88–91.
74. Muller A, Octavio J, Gonzalez MY, Contreras J, Mendez G, Portillo M, et al. Clinical bioequivalence of a dose of clopidogrel Leti Cravid tablets 75 mg versus clopidogrel Sanofi Plavix tablets 75 mg administered on a daily dose for 7 days on healthy volunteers: a clinical trial. Am J Ther. 2010;17(3):351–6. doi:10.1097/MJT.0b013e3181c15221.
75. Oberhansli M, Lehner C, Puricel S, Lehmann S, Togni M, Stauffer JC, et al. A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: the CLO-CLO trial. Arch Cardiovasc Dis. 2012;105(11):587–92. doi:10.1016/j.acvd.2012.06.001.
76. Park JB, Koo BK, Choi WG, Kim SY, Park J, Kwan J et al. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial. Clin Ther. 2013;35(1):28–37e4. doi:10.1016/j.clinthera.2012.12.004.
77. Seo KW, Tahk SJ, Yang HM, Yoon MH, Shin JH, Choi SY, et al. Point-of-care measurements of platelet inhibition after clopidogrel loading in patients with acute coronary syndrome: comparison of generic and branded clopidogrel bisulfate. Clin Ther. 2014;36(11):1588–94. doi:10.1016/j.clinthera.2014.07.018.
78. Srimahachota S, Rojnuckarin P, Udayachalerm W, Buddhari W, Chaipromprasit J, Lertsuwunseri V, et al. Comparison of original and generic clopidogrel 600 mg loading dose in the patients who planned undergoing coronary angiography. J Med Assoc Thai. 2012;95(12):1495–500.
79. Tsoumani ME, Kalantzi KI, Dimitriou AA, Ntalas IV, Goudevenos IA, Tselepis AD. Antiplatelet efficacy of long-term treatment with clopidogrel besylate in patients with a history of acute coronary syndrome: comparison with clopidogrel hydrogen sulfate. Angiology. 2012;63(7):547–51. doi:10.1177/0003319711427697.
80. Tsoumani ME, Kalantzi KI, Dimitriou AA, Ntalas IV, Goudevenos IA, Tselepis AD. Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes: comparison with clopidogrel hydrogen sulfate. Expert Opin Pharmacother. 2012;13(2):149–58. doi:10.1517/14656566.2012.644536.
81. Zou JJ, Tan J, Fan HW, Chen SL. Bioequivalence study of clopidogrel 75 mg tablets in healthy male volunteers. J Bioequiv Bioavailab. 2012;4:6–9. doi:10.4172/jbb.1000102.
82. Biswas NR, Garg SK, Kumar N, Mukherjee S, Sharma PL. Comparative pharmacokinetic and pharmacodynamic study of four different brands of propranolol in normal volunteers. Int J Clin Pharmacol Ther Toxicol. 1989;27(10):515–9.
83. Bus-Kwasnik K, Ksycinska H, Les A, Serafin-Byczak K, Rudzki PJ, Raszek J, et al. Bioequivalence and pharmacokinetics of two 10-mg bisoprolol formulations as film-coated tablets in healthy white volunteers: a randomized, crossover, open-label, 2-period, single-dose, fasting study. Int J Clin Pharmacol Ther. 2012;50(12):909–19. doi:10.5414/CP201726.
84. Liu Y, Lu C, Chen Q, Wang W, Liu GY, Lu XP, et al. Bioequivalence and pharmacokinetic evaluation of two tablet formulations of carvedilol 25-mg: a single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. Drug Res (Stuttg). 2013;63(2):74–8. doi:10.1055/s-0032-1331768.
85. Kim SA, Park S, Chung N, Lim DS, Yang JY, Oh BH, et al. Efficacy and safety profiles of a new S(−)-amlodipine nicotinate formulation versus racemic amlodipine besylate in adult Korean patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, double-dummy, parallel-group, phase III, noninferiority clinical trial. Clin Ther. 2008;30(5):845–57. doi:10.1016/j.clinthera.2008.05.013.
86. Liu Y, Jia J, Liu G, Li S, Lu C, Yu C. Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. Clin Ther. 2009;31(4):777–83. doi:10.1016/j.clinthera.2009.04.013.
87. Almeida S, Pedroso P, Filipe A, Pinho C, Neves R, Jimenez C, et al. Study on the bioequivalence of two formulations of eplerenone in healthy volunteers under fasting conditions: data from a single-center, randomized, single-dose, open-label, 2-way crossover bioequivalence study. Arzneimittelforschung. 2011;61(3):153–9. doi:10.1055/s-0031-1296182.
88. Kumar S, Monif T, Khuroo A, Reyar S, Jain R, Singla AK, et al. Pharmacokinetic comparison and bioequivalence evaluation of losartan/hydrochlorothiazide tablet between Asian Indian and Japanese volunteers. Int J Clin Pharmacol Ther. 2014;52(1):39–54. doi:10.5414/CP201927.
89. Boh M, Opolski G, Poredos P, Ceska R, Jezovnik M. Therapeutic equivalence of the generic and the reference atorvastatin in patients with increased coronary risk. Int Angiol. 2011;30(4):366–74.
90. Feng L, Shen-Tu J, Liu J, Chen J, Wu L, Huang M. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects. Clin Ther. 2009;31(7):1559–67. doi:10.1016/j.clinthera.2009.07.017.
91. Kim SH, Park K, Hong SJ, Cho YS, Sung JD, Moon GW, et al. Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trial. Clin Ther. 2010;32(11):1896–905. doi:10.1016/j.clinthera.2010.10.004.
92. Kim SH, Seo MK, Yoon MH, Choi DH, Hong TJ, Kim HS. Assessment of the efficacy and tolerability of 2 formulations of atorvastatin in Korean adults with hypercholesterolemia: a multicenter, prospective, open-label, randomized trial. Clin Ther. 2013;35(1):77–86. doi:10.1016/j.clinthera.2012.11.009.
93. Liu YM, Pu HH, Liu GY, Jia JY, Weng LP, Xu RJ, et al. Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. Clin Ther. 2010;32(7):1396–407. doi:10.1016/j.clinthera.2010.07.004.
94. Palmer JL, Kunhihitlu A, Costantini A, Esquivel F, Roush J, Edwards K, Hill TWK. Pharmacokinetic bioequivalence crossover study of branded generic and innovator formulations of the cholesterol lowering agent ezetimibe. Clin Pharmacol Drug Dev. 2014;3(3):242–8.
95. Shim CY, Park S, Song JW, Lee SH, Kim JS, Chung N. Comparison of effects of two different formulations of clopidogrel bisulfate tablets on platelet aggregation and bleeding time in healthy Korean volunteers: a single-dose, randomized, open-label, 1-week, two-period, phase IV crossover study. Clin Ther. 2010;32(9):1664–73. doi:10.1016/j.clinthera.2010.08.001.
96. Suh JW, Seung KB, Gwak CH, Kim KS, Hong SJ, Park TH, et al. Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: a phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial. Clin Ther. 2011;33(8):1057–68. doi:10.1016/j.clinthera.2011.07.001.
97. Shrank WH, Cox ER, Fischer MA, Mehta J, Choudhry NK. Patients’ perceptions of generic medications. Health Aff (Millwood). 2009;28(2):546–56. doi:10.1377/hlthaff.28.2.546.
98. Shrank WH, Liberman JN, Fischer MA, Girdish C, Brennan TA, Choudhry NK. Physician perceptions about generic drugs. Ann Pharmacother. 2011;45(1):31–8. doi:10.1345/aph.1P389.
99. Himmel W, Simmenroth-Nayda A, Niebling W, Ledig T, Jansen RD, Kochen MM, et al. What do primary care patients think about generic drugs? Int J Clin Pharmacol Ther. 2005;43(10):472–9.
100. Corrao G, Soranna D, Arfe A, Casula M, Tragni E, Merlino L, et al. Are generic and brand-name statins clinically equivalent? Evidence from a real data-base. Eur J Intern Med. 2014;25(8):745–50. doi:10.1016/j.ejim.2014.08.002.
101. Gagne JJ, Choudhry NK, Kesselheim AS, Polinski JM, Hutchins D, Matlin OS, et al. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. Ann Intern Med. 2014;161(6):400–7. doi:10.7326/M13-2942.
102. IMS Health. Generic Medicines: Essential contributors to the long-term health of society. London: IMS Health; 2013.
103. OECD. Pharmaceutical generic market share, in Health at a Glance 2013: OECD indicators. Paris: OECD Publishing; 2013. doi:10.1787/health_glance-2013-42-en.
104. The Global Use of Medicines: outlook through 2017. IMS Institute for Healthcare Informatics. 2013. http://www.imshealth.com/cds/imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Reports/Global_Use_of_Meds_Outlook_2017/IIHI_Global_Use_of_Meds_Report_2013.pdf. Accessed December 2014.
105. The Cardiovascular Market Outlook to 2016. Business insights. 2011. http://download.bioon.com.cn/view/upload/201303/16084307_4163.pdf. Accessed December 2014.
106. Nilsen V, Bakke PS, Gallefoss F. Effects of lifestyle intervention in persons at risk for type 2 diabetes mellitus: results from a randomised, controlled trial. BMC Public Health. 2011;11:893. doi:10.1186/1471-2458-11-893.
107. Manzoli L, Flacco ME, D’Addario M, Capasso L, De Vito C, Marzuillo C, et al. Non-publication and delayed publication of randomized trials on vaccines: survey. BMJ. 2014;348:g3058. doi:10.1136/bmj.g3058.
108. International Committee of Medical Journal Editors (ICMJE). Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. 2014. http://www.icmje.org/icmje-recommendations.pdf.
109. Faasse K, Cundy T, Gamble G, Petrie KJ. The effect of an apparent change to a branded or generic medication on drug effectiveness and side effects. Psychosom Med. 2013;75(1):90–6. doi:10.1097/PSY.0b013e3182738826.
110. Alpern JD, Stauffer WM, Kesselheim AS. High-cost generic drugs-implications for patients and policymakers. N Engl J Med. 2014;371(20):1859–62. doi:10.1056/NEJMp1408376.
111. Shrank WH, Choudhry NK, Liberman JN, Brennan TA. The use of generic drugs in prevention of chronic disease is far more cost-effective than thought, and may save money. Health Aff (Millwood). 2011;30(7):1351–7. doi:10.1377/hlthaff.2010.0431.
112. Jackevicius CA, Chou MM, Ross JS, Shah ND, Krumholz HM. Generic atorvastatin and health care costs. N Engl J Med. 2012;366(3):201–4. doi:10.1056/NEJMp1113112.